Cargando…
T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab
CD6 is associated with T-cell modulation and is implicated in several autoimmune diseases. We previously demonstrated that Itolizumab, a CD6 domain 1 (CD6D1) specific humanized monoclonal antibody, inhibited the proliferation and cytokine production by T lymphocytes stimulated with anti-CD3 antibody...
Autores principales: | Bughani, Usha, Saha, Arindam, Kuriakose, Anshu, Nair, Reshmi, Sadashivarao, Ravindra B., Venkataraman, Rasika, Patel, Swati, Deshchougule, Anuja Tushar, S., Satish Kumar, Montero, Enrique, Pai, Harish V., Palanivelu, Dinesh V., Melarkode, Ramakrishnan, Nair, Pradip |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5495335/ https://www.ncbi.nlm.nih.gov/pubmed/28672038 http://dx.doi.org/10.1371/journal.pone.0180088 |
Ejemplares similares
-
Correction: T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab
por: Bughani, Usha, et al.
Publicado: (2018) -
Itolizumab in Psoriasis
por: Srivastava, Ankita
Publicado: (2017) -
EGFR targeting monoclonal antibody combines with an mTOR inhibitor and potentiates tumor inhibition by acting on complementary signaling hubs
por: James, Roshan, et al.
Publicado: (2012) -
Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications
por: Kuriakose, Anshu, et al.
Publicado: (2016) -
BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth
por: Boreddy, Srinivas Reddy, et al.
Publicado: (2023)